MAP2K7 and melanoma: In this study, we found that the EPE peptide also reduces the viability of NRAS and some NF1 mutant melanomas as well, and combination of EPE peptide and MEK inhibitor trametinib showed synergy in reducing the growth of other melanomas, including those resistant to each drug alone.